Equities

Shockwave Medical Inc

Shockwave Medical Inc

Actions
  • Price (USD)330.68
  • Today's Change0.14 / 0.04%
  • Shares traded30.42k
  • 1 Year change+14.35%
  • Beta1.0718
Data delayed at least 15 minutes, as of May 10 2024 15:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Shockwave Medical, Inc. is a medical device company. The Company is primarily engaged in the development and commercialization of novel technologies that transform the care of patients with cardiovascular disease. The Company is focused on its intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral vascular, coronary vascular and heart valve disease. Built on a balloon catheter platform, the IVL technology uses lithotripsy to disrupt both superficial and deep vascular calcium., while minimizing soft tissue injury, and an integrated angioplasty balloon to dilate blockages at low pressures, restoring blood flow. Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD.

  • Revenue in USD (TTM)787.97m
  • Net income in USD163.50m
  • Incorporated2009
  • Employees1.47k
  • Location
    Shockwave Medical Inc5403 Betsy Ross DrSANTA CLARA 95054United StatesUSA
  • Phone+1 (510) 279-4262
  • Fax+1 (302) 636-5454
  • Websitehttps://shockwavemedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Stevanato Group SpA1.17bn157.00m6.37bn5.64k35.634.5726.355.440.59220.59224.414.610.58183.142.75207,651.707.81--10.81--32.28--13.42--1.0619.740.2593--10.34--1.95------
Masimo Corp1.98bn79.10m6.57bn3.80k84.804.8337.433.321.461.4636.5425.710.65072.015.24519,973.702.608.653.1710.3148.6157.304.0012.031.313.610.39090.000.604219.00-43.21-15.9631.06--
MSA Safety Inc1.80bn266.82m7.47bn5.10k28.187.5422.734.146.736.7345.4925.260.82812.866.45353,467.8012.265.0814.256.0048.0545.2114.817.021.546.500.374765.9117.005.65-67.41-13.664.72-1.10
Penumbra Inc1.10bn93.39m8.12bn4.20k88.106.7466.757.412.382.3827.9031.050.73661.035.49260,899.806.282.326.982.6165.0463.908.523.173.51--0.02070.0024.9518.934,643.1668.609.64--
Globus Medical Inc1.90bn66.63m8.69bn5.00k101.842.2234.834.580.6320.63215.4829.040.53531.265.01379,690.801.886.902.177.4562.1471.733.5114.051.29--0.09770.0053.3417.08-35.39-4.725.57--
Henry Schein, Inc.12.45bn388.00m9.44bn25.00k24.822.6214.250.75782.962.9695.1128.021.334.748.00498,040.004.206.096.8010.4431.3830.043.164.401.028.260.32070.00-2.445.55-22.68-0.145621.27--
Teleflex Inc3.00bn296.02m9.64bn14.50k32.722.1417.713.216.266.2363.4195.610.4172.146.99206,993.504.115.864.476.4255.7055.049.8614.621.417.670.280815.846.573.97-1.4712.732.510.00
Shockwave Medical Inc787.97m163.50m12.41bn1.47k77.4616.0970.8115.754.274.2720.5820.550.64931.057.55536,763.6013.4710.2914.9111.3986.9984.6920.7515.1412.61--0.49360.0049.11126.45-31.81--72.88--
Insulet Corp1.70bn206.30m12.43bn3.00k63.0016.9444.547.322.822.8222.7810.480.70141.436.00565,700.008.532.7110.263.1468.3565.8112.164.282.6240.740.6590.0030.0224.664,384.78128.77-7.63--
Hologic Inc3.96bn466.50m17.68bn6.99k38.973.6522.514.461.941.9416.3020.760.43612.665.82566,609.405.1411.405.7413.3855.1260.2911.7820.953.29--0.34650.00-17.124.61-64.98--7.30--
Baxter International Inc14.89bn-38.00m18.32bn60.00k--2.2414.671.23-0.07625.2129.3316.040.53113.215.71248,200.00-0.1070.1942-0.13380.233336.3138.20-0.20150.36741.013.580.6251,398.942.125.9497.15--0.9829.71
Data as of May 10 2024. Currency figures normalised to Shockwave Medical Inc's reporting currency: US Dollar USD

Institutional shareholders

44.91%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 20233.58m9.57%
BlackRock Fund Advisorsas of 31 Dec 20233.30m8.83%
Wellington Management Co. LLPas of 31 Dec 20232.47m6.61%
Fidelity Management & Research Co. LLCas of 31 Dec 20231.93m5.16%
Artisan Partners LPas of 31 Dec 20231.50m4.00%
SSgA Funds Management, Inc.as of 31 Dec 20231.06m2.85%
Citadel Advisors LLCas of 31 Dec 2023833.45k2.23%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023769.50k2.06%
JPMorgan Investment Management, Inc.as of 31 Dec 2023747.99k2.00%
Geode Capital Management LLCas of 31 Dec 2023601.19k1.61%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.